BioForest

Found 21,571 articles

• Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences

  3/20/2023

  Alpine Immune Sciences, Inc. (NASDAQ: ALPN) will present posters at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting and at the International Society of Nephrology World Congress of Nephrology (WCN).

• Public Advisory - Two lots of cystic fibrosis drug Cayston recalled due to the potential of cracked glass vials

  3/18/2023

  Health Canada is advising the public that Gilead Sciences Incorporated recalled two lots of the cystic fibrosis drug Cayston on March 1, 2023, due to the potential of cracked glass vials in those lots, which may introduce glass particles into the medication.

• Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

  3/17/2023

  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023.

• Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023

  3/17/2023

  Impel Pharmaceuticals Inc. today announced it will host a live webcast on Friday, March 24, 2023, at 8:30 a.m. ET to report its fourth quarter and full year 2022 financial results and provide a business update.

• Jubilant HollisterStier Announces New President and Upcoming Availability of Expanded Production Capacity for Sterile Injectables

  3/16/2023

  Jubilant HollisterStier, a leading US-based pharmaceutical contract manufacturer of sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products announces the appointment of Chris Preti as President.

• Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

  3/16/2023

  Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.

• Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb

  3/16/2023

  Evotec SE announced progress within the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.

• BioLife Solutions Reports Preliminary and Unaudited 2022 Fourth Quarter and Full Year Financial Results

  3/16/2023

  BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company") today announced financial results for the fourth quarter and year ended December 31, 2022.

• Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting

  3/16/2023

  Alpine Immune Sciences, Inc. (NASDAQ: ALPN) will present an ePoster with an oral presentation at the American Academy of Dermatology (AAD) Annual Meeting, highlighting clinical data from RUBY-1, a phase 1 healthy volunteer (HV) study of povetacicept, a dual B cell cytokine antagonist being developed for multiple B cell and/or autoantibody-related diseases.

• LumiThera Announces Sustained Vision Improvement for 24 months in Dry Age-Related Macular Degeneration Subjects from US LIGHTSITE III Clinical Trial Data

  3/15/2023

  LumiThera Inc. today announced the 24-month data from its LIGHTSITE III, multi-center clinical trial which demonstrated sustained vision improvement in dry Age-Related Macular Degeneration (AMD) subjects treated with the Valeda ® Light Delivery System.

• OnQuality Pharmaceuticals Announces Presentations of OQL025 and OQL06x, at the AACR Annual Meeting

  3/15/2023

  OnQuality Pharmaceuticals today announced it will present preclinical data for its two drug candidates, OQL025 and OQL06x, at the upcoming American Association for Cancer Research (AACR) annual meeting.

• OncoResponse Announces Presentation of Preclinical Data on Dual Antibodies Targeting LILRB1 and LILRB2 at American Association for Cancer Research Annual Meeting 2023 (AACR 2023)

  3/15/2023

  OncoResponse today announced a poster presentation at the upcoming American Association for Cancer Research Annual Meeting being held April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.

• Kurve Therapeutics, Inc. Announces Development of New Intellectual Property to Target Drug Delivery in the Brain

  3/15/2023

  Today, Kurve Therapeutics (Kurve Tx) announced it has filed for new intellectual property on its nose-to-brain technology platform.

• Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results

  3/15/2023

  Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2022 financial results on Thursday, March 23, 2023, after the close of market.

• EMulate Therapeutics Announces the Addition of Donna Morgan Murray, Ph.D., to its Board of Directors

  3/14/2023

  EMulate Therapeutics, Inc. today announced the addition of Donna Morgan Murray, Ph.D. to the Company’s board of directors.

• Perspective Therapeutics and PharmaLogic announce collaboration for the development and production of theranostics for cancer care

  3/14/2023

  PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company") today announces the signature of a Master Services Agreement with Viewpoint Molecular Targeting, Inc., a wholly-owned subsidiary of Perspective Therapeutics, Inc. ("Perspective") (NYSE AMERICAN: CATX), for the development and production of theranostic candidates VMT-01 and VMT-α-NET.

• Curi Bio Launches MantaReady™ 3D Skeletal Muscle Tissue Media

  3/14/2023

  Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of their MantaReady™ Skeletal Muscle Media optimized for human 3D engineered muscle tissue experiments.

• Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting

  3/14/2023

  Sana Biotechnology, Inc. announced that four abstracts, including a late-breaking abstract, highlighting preclinical data from both the hypoimmune and fusogen platforms have been accepted for poster presentation at the 2023 American Association for Cancer Research Annual Meeting taking place April 14-19, 2023 in Orlando, FL.

• Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting

  3/14/2023

  Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts featuring new clinical and preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando from April 14-19, 2023.

• Gestalt and Pramana Announce Strategic Partnership to Offer Customers Advanced, AI-Enabled Image Analysis in End-to-End Solution

  3/13/2023

  Gestalt Diagnostics Inc. and Pramana, Inc. announced a strategic collaboration to provide an AI-powered, end-to-end digital pathology platform for laboratories, health systems and academic medical centers.